Slide 1: Corporate presentation
Corporate Corpora ate presentation presentattioon March 20177 2%1 2%1,.*)<$%,()8 1,.*)<$%,()88 1,.*)A*(+1(%-9*(91 1 1,.*)A*(+1(%-9*(91 2% 2% 3-*)<%,.*,8 3-*)<%,.*,8 '3-*)A*(+1(%-9*(91 '3-*)A*(+1(%-9*(91 Sleep Sleep Diagnostics Diagnostics & Treatment Treatment - Neuro Neuro Diagnostics Diaggnostics
Slide 2: Who is Compumedics?
Who is Compumedics? A leading global, innovative developer and manufacturer of medical devices for: Monitoring neurological Ultrasonic monitoring Diagnosing disorders including Highly sophisticated of blood flow through sleep disorders long-term epilepsy brain research the brain (Transcranial monito
Slide 3: H1 FY2018 – Performance Review
H1 FY2018 – Performance Review H1 FY18 Revenue (reported) $16.1m, EBITDA (reported) $1.1m, NPAT (reported) $0.6m &&( &&' $*(+)5.**&,*,-'-*,,-%) H HO*DHO9L(8%)'1%)#.$,-. -'- *,,9*(*.$--'-*,,-3,)*. 2)1; DHM9H( DHM9I( ;S? **&1)/''.%) HIO).$ ,+*,. *,,%-%)#+,+,*,-$%+().%) I HO8-,-1'..$*(+)5#),. DHM9H(%)-
Slide 4: H1 FY2018 – Performance Review
H1 FY2018 – Performance Review Record H1 sales orders – $18.5m, including the first MEG sales order. Sales orders received, but not shipped, at 31 December 2017 are $6.5m compared to $3.0m at 31 December 2016 US business sales orders 49% higher than H1 FY17, indicating changes made during 2017 are t
Slide 5: Sales Bridge Chart – H1 FY17 versus H1 FY18
Sales Bridge Chart – H1 FY17 versus H1 FY18 IG HO HM HK HI HG O M K I G '- HHM 1-. -% /)(,% 1,*+ '- HHN '' - 5
Slide 6: EBITDA movement – H1 FY17 versus H1 FY18
EBITDA movement – H1 FY17 versus H1 FY18 H9O H9M H9K H9I H G9O G9M G9K G9I G HHN '- ,#%) 4+)-- .$,2)1- 7HO '' - 6
Slide 7: H1 v H2 – FY17 actual to FY18 actual/forecast
H1 v H2 – FY17 actual to FY18 actual/forecast 7
Slide 8: H1 v H2 – FY17 actual to FY18 actual/forecast
H1 v H2 – FY17 actual to FY18 actual/forecast Orders taken in H1 FY18 were $18.5m compared to $15.5 for H1 FY17. Carry forward orders booked but not shipped at 31 December 2017 are $6.5m, compared to $3.0m at 31 December 2016 The MEG sale to BNI is scheduled to ship H2 FY18 The US business is expect
Slide 9: H1 FY18 – Milestones achieved
H1 FY18 – Milestones achieved Core business: Profitability grows, with constant sales, validating changes made to product composition (new low cost Grael® devices) and the selective outsourcing of production, along with other efficiency gains MEG: Compumedics/Neuroscan continues to build its new MEG
Slide 10: Revenue Composition at $16.1m for H1 FY18
Revenue Composition at $16.1m for H1 FY18 31 December 2017 By geographic region By product/market Tech. Supply Service; Items; Europe; 11% 27% USA; Brain 10% 35% Blood Flow; Sleep; 15% 32% Asia; Brain Aust; Res; Neuro; 24% 14% 24% 7% Software upgrades 5 to 10% of system sales Compumedics sells direc
Slide 11: Core Business – Continuing Net Cash Position
Core Business – Continuing Net Cash Position $m FY13 FY14 FY15 FY16 H1 FY17 H1 FY18 Cash 1.3 1.1 2.2 3.1 5.7 2.9 Trade receivables 8.1 8.6 9.8 11.9 10.9 14.8 Inventories 5.5 6.1 5.7 6.5 7.1 7.7 Prod. dev’t 3.5 2.9 2.7 2.4 2.4 3.4 Tax asset 0.0 0.0 0.0 0.5 0.5 0.7 PP&E 0.7 0.7 0.8 0.8 0.8 0.6 Other 0
Slide 12: Outlook
Outlook Profitability and operating cash remain positive, despite sales shortfall, validating changes made to product composition (new low cost Grael devices) and the selective outsourcing of production, along with other efficiency gains US management and sales team changes delivering results. US sa
Slide 13: Growth Platform – Core and Step-Out
Growth Platform – Core and Step-Out '-–-$(/*)'5 HO HP IG IH II *,;- *,;'+: 1,*= % ,&.> 1,*; '+; '.$= 41-JMG@*(.> • "! " # <%))%)#.$)3 ?-'3%.$,,*3 1,*'*#%' )-/.1.%) $*)%4882'%.-.$.3).,)-%/*),*(JG&-*"3,-'.*K9G(*(+'. -5-.(-'9'%2,5.,&%)#.* IHO8*.$,-'-*++*,.1)%/-%)#+1,-19 • "! " " < 41-JMG'*1;-+,*--%*)'-
Slide 14: Core Business – Premium Focus
Core Business – Premium Focus Neuro Neuro Sleep Brain Blood Diagnostics – Diagnostics - Diagnostics Flow Diagnostics Clinic Research Global market – 250m 1,300m 20m 15m USD pa Compumedics market share 6% <1% 30% 35% (approximate) Aust – 1 Aust – 1 Aust – 1 Aust – 1 Compumedics USA – 2 USA – 3 USA –
Slide 15: Core Business – Adding Mid-Tier Range
Core Business – Adding Mid-Tier Range Average Product Used for Bought by selling price Hospitals, doctors Grael Sleep and neurology USD17,500 and service providers Hospitals, doctors Somte PSG Sleep USD10,000 and service providers Hospitals, doctors Siesta Sleep and neurology USD18,000 and service p
Slide 16: Next Generation Growth – Core and Step-out
Next Generation Growth – Core and Step-out Neuro Neuro Sleep Brain Blood Diagnostics – Diagnostics - Diagnostics Flow Diagnostics Clinic Imaging Cloud based sleep Leverage existing Long term epilepsy diagnostic platforms Leverage CURRY TCD technology and Next generation market penetration for both p
Slide 17: Core Business - Growth Drivers
Core Business - Growth Drivers Compumedics/NeuroScan LTEM innovative brain analysis software and high performance amplifiers are unrivalled world class technology We have >20,000 systems installed worldwide. Strong reputation and brand name. Customers like buying from Compumedics. Earnings initiativ
Slide 18: USA – CMP is number 3 Supplier
USA – CMP is number 3 Supplier USA Clinical Sales Force Expansion - Indicative More sales representatives = more revenue for both sleep and neurology Past USD4.0m FY2017 to now USD3.2m FY2018 USD7.0m FY2019 USD11.0m 18
Slide 19: China - We are the number 1 Premier Supplier
China - We are the number 1 Premier Supplier Compumedics Clients in China Sleep Neuroscience Neuroscan 28 2 Xin Jiang 5 Helongjiang Inner Mongolia 2 Jilin Beijing 88 2 Liaoning Ningxia 23 Qinhuangdao China Sales (invoiced) – USD’s QingHai 3 HeBei 10 3 Tianjin Dalian 2 3 16 12 7.5 7.4 Gansu 14 HeNan
Slide 20: Step out 1 - Brain Imaging: 1st sale tracking to delivery
Step out 1 - Brain Imaging: 1st sale tracking to delivery Opportunity Market & Competition Plan Outcome CMP’s CURRY brain The MEG market is currently H2 FY18 – ship and CMP plans to sell analysis software is already estimated at about 20 systems a install first MEG sale and install 1 MEG the gold st
Slide 21: Step out - eHealth – Cloud Sleep Diagnostics
Step out 2 - eHealth – Cloud Sleep Diagnostics Nexus 360 Operational systems have Compumedics are Key partners (professional been developed for the cloud now approaching being cloud sleep based capture, transfer a select group of pursued diagnostics) and translation of medical grade strategic partne
Slide 22: Directors & Executive Team Key Management
Directors & Executive Team Key Management David Burton, Ph.D. Executive Chairman, CEO Founder, Tenure 30yrs NED - Mr. Alan Anderson Mr. David Lawson Leading USA Attorney Chief Financial Officer CMP Tenure : 18 yrs & Company Secretary CMP Tenure 19 yrs Mr. Warwick Freeman Kerry Hubick, Ph.D. Mr. Chri
Slide 23: Investor Summary
Investor Summary Core business continues to grow with lower cost base and addition of mid-tier International sales force Compumedics remains expansion, neurology market committed to continuing to opportunity and earnings deliver superior returns to improvement initiatives to shareholders continue to
Slide 24: THANK YOU
© COMPUMEDICS THANK YOU NEXUS 360" Laboratory Management System YEARS OF EXCELLENCE IN DIAGNOSTICS.
Slide 25: Disclaimer
Disclaimer This presentation has been prepared by Compumedics Ltd (CMP). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estim
Slide 26: compumedics.com.au
CG COMPUMEDICS AK NV VRSF ZZ UNA } r 2 Z VEN EF ISSC ANGE i’ TH p SSO y | eS, S< | a WA i iN / Lyf) h BM Y o, v iF a KAT). VA aa